Answers are grounded in this paper and cite their sources.
In pulmonary arterial hypertension (PAH), comparative assessment of treatment effect on survival in randomized controlled settings of contemporary patients has not been feasible. The aim of this study was to use EXPOSURE, the ongoing, real-world, post-authorization safety study, and commitment to the European Medicines Agency to perform pre-specified comparative survival analyses between patients that newly initiated selexipag versus other PAH-specific therapies by applying statistical methods to account for population differences. EXPOSURE (EUPAS19085) is an observational study comprising patients with PAH who initiated selexipag or other PAH-specific therapy. To balance characteristics of patients in the other PAH therapy cohort with the selexipag cohort at PAH therapy initiation (baseline), propensity score weighting was applied. Mortality rate ratios (MRRs) were calculated. 2014 patients were available for analysis. Prior to applying propensity score weighting, patients in the selexipag cohort were more likely to have longer time from diagnosis, less functional impairment, and treatment with combination background therapy versus the other PAH therapy cohort. Following weighting, baseline variables for both cohorts were well balanced. Weighted treatment exposure was 827.9 and 840.5 person-years for the selexipag and modelled other PAH therapy cohort, respectively. Weighted proportion of deaths was lower in the selexipag versus modelled other PAH therapy cohort; MRR showed a higher survival rate for selexipag-treated patients (MRR [95% confidence interval]: 0.55 [0.31–0.99]). Survival analyses in EXPOSURE suggest a reduced risk of mortality among the cohort of patients newly initiated on selexipag compared with the modelled cohort newly initiated with other PAH-specific therapies. Further research is needed to confirm this observation. Trial registration: EUPAS19085. Pulmonary arterial hypertension (PAH) is a rare and progressive disease characterized by high blood pressure in the blood vessels of the lungs. The rare and progressive nature of the disease makes measuring the effect of treatments on survival in randomized controlled trials challenging. To investigate this, we used real-world data from the EXPOSURE study (EUPAS19085), along with advanced statistical methods of modelling. Our observations indicate that the relative risk of dying was lower with selexipag treatment compared with other PAH therapies. EXPOSURE is a post-approval study required by the European Medicines Agency, aimed at collecting data on patients with PAH who are starting a new PAH treatment in medical clinics. We analyzed 2014 patients, divided into two groups: one that started treatment with selexipag (selexipag group) and another that started other PAH medication(s) (other PAH therapy group). At the start of treatment, patients in the selexipag group had been diagnosed with PAH for longer and showed less severe symptoms compared with the other PAH therapy group. They were also more likely to be on a combination of at least two different PAH medications at the time they started treatment with selexipag. Because of these differences, we used statistical modelling to balance patient characteristics at the start of treatment to be able to compare the medications. After balancing the groups, our data suggest a lower relative risk of dying with selexipag treatment compared with treatment with other PAH therapies.
No takes yet. Share an insight, caveat, or question.
Söderberg et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: